Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a significant decreased risk for adverse clinical outcomes including becoming unconscious, hypoxia (body starved for oxygen) and death.
In addition, they had lower blood levels of an inflammatory marker (C-reactive protein) and higher blood levels of lymphocytes (a type of immune cell to help fight infection).
“This study provides direct evidence that vitamin D sufficiency can reduce the complications, including the cytokine storm (release of too many proteins into the blood too quickly) and ultimately death from COVID-19,” explained corresponding author Michael F. Holick, Ph.D., MD, professor of medicine, physiology and biophysics and molecular medicine at Boston University School of Medicine.
A blood sample to measure vitamin D status (measured serum level of 25-hydroxyvitamin D) was taken from 235 patients were admitted to the hospital with COVID-19.
These patients were followed for clinical outcomes including clinical severity of the infection, becoming unconscious, having difficulty in breathing resulting in hypoxia and death.
The blood was also analyze for an inflammatory marker (C-reactive protein) and for numbers of lymphocytes.
The researchers then compared all of these parameters in patients who were vitamin D deficient to those who were vitamin D sufficient.
In patients older than 40 years they observed that those patients who were vitamin D sufficient were 51.5 percent less likely to die from the infection compared to patients who were vitamin D deficient or insufficient with a blood level of 25-hydroxyvitamin D less than 30 ng/mL.
Holick, who most recently published a study which found that a sufficient amount of vitamin D can reduce the risk of catching coronavirus by 54 percent, believes that being vitamin D sufficient helps to fight consequences from being infected not only with the corona virus but also other viruses causing upper respiratory tract illnesses including influenza.
“There is great concern that the combination of an influenza infection and a coronal viral infection could substantially increase hospitalizations and death due to complications from these viral infections.”
According to Holick this study provides a simple and cost-effective strategy to improve one’s ability to fight the corona virus and reduce COVID-19’s adverse clinical outcomes, including requiring ventilator support, overactive immune response leading to cytokine storm and death.
“Because vitamin D deficiency and insufficiency is so widespread in children and adults in the United States and worldwide, especially in the winter months, it is prudent for everyone to take a vitamin D supplement to reduce risk of being infected and having complications from COVID-19.”
Potential mechanisms linking COVID-19 and vitamin D
In COVID-19 patients the severity of the illness is frequently determined by the presence of pneumonia/acute respiratory distress syndrome (ARDS), myocarditis, microvascular thrombosis and/or cytokine storm, all of which involve underlying inflammation.
While the COVID-19-specific CD8 T cells and the specific antibodies produced by B cells are critical for eliminating the virus, uncontrolled non-specific inflammation and cytokine release can cause catastrophic injury to the lungs and other vital organs.
Consequently, decreasing this early non-specific inflammation during COVID-19 may provide time for the development of specific acquired immunity against COVID-19.
A principal defence against uncontrolled inflammation, and against viral infection in general, is provided by T regulatory lymphocytes (Tregs).
Treg levels have been reported to be low in one group of COVID-19 patients, and ‘markedly lower in severe cases’.1
In a study of older nursing home patients, high Treg blood levels were found to be associated with a reduced level of respiratory viral disease.2
These observations suggest that if Treg levels can be increased, this might be of benefit in diminishing the severity of viral disease and perhaps of COVID-19.
Treg levels can be increased by vitamin D supplementation.3,4 The importance of vitamin D in cases of respiratory infection is illustrated by the fact that low vitamin D levels are common in populations worldwide and low levels have been associated with a significantly increased risk of pneumonia5 and viral upper respiratory tract infections.6
Vitamin D deficiency (serum 25-hydroxyvitamin D (25(OH)D) <50 nmol/L) is present in 30–60% of the populations of western, southern and eastern Europe and in up to 80% of populations in middle-eastern countries.7
In addition, even more severe deficiency (serum levels <30 nmol/L) is reported in over 10% of Europeans.
Low levels of vitamin D are also associated with an increase in inflammatory cytokines.
A study of healthy women in the USA found a significant inverse relationship between the serum levels of 25(OH)D and TNF-alpha.8 In another report, the levels of IL6 were found to be increased in those who were vitamin D deficient.
In a wide variety of animal studies and in vitro cell models, vitamin D3 has been demonstrated to downregulate the production of inflammatory cytokines, such as TNF-alpha and IL6, while increasing inhibitory cytokines.9
These studies raise the possibility that adequate levels of vitamin D may reduce the incidence of cytokine storm, which can occur in COVID-19.
Thrombotic complications are common in COVID-19 patients.10
Of those with severe disease, over half have been found to have elevated D-dimer levels. Interestingly, vitamin D is also involved in the regulation of thrombotic pathways, and vitamin D deficiency is associated with an increase in thrombotic episodes.11
Vitamin D deficiency has also been found to occur more frequently in patients with obesity and diabetes. These conditions are reported to carry a higher mortality in COVID-19. An increased risk of death with COVID-19 is also observed in black, Asian and minority ethnic (BAME) groups.
As melanin reduces the production of vitamin D sociated with exposure to the ultraviolet radiation in sunlight, this may help to explain the observed frequent occurrence of vitamin D deficiency in BAME groups.
One recurring question regarding COVID-19 is whether, once a patient has had the infection, they are unlikely to be re-infected at a later date. The answer to that question is still unknown and depends to some extent on the production, longevity and efficacy of the specific antibodies.
However, in the case of influenza A virus (IAV), exposure to the virus results in the production of memory regulatory T cells (mTregs), which persist in the host.12 In mice exposed to influenza A infection, the infusion of mTregs into their tail vein significantly reduces weight loss and lung pathology (particularly the inflammatory infiltrate), relative to the infusion of Tregs that have not previously been exposed to the virus.
This study illustrates the potential efficacy of Tregs in combatting viral infection. Given that women have higher levels of Treg cells than men,13 the observation might provide one reason why women have a lower mortality when infected by COVID-19.
Should we supplement with vitamin D?
Based on these findings, we ask three questions. Do patients hospitalised with severe COVID-19 illness have lower vitamin D and Treg levels than COVID-19 positive patients whose illness is milder and who remain quarantined at home?
Does vitamin D supplementation increase Tregs in these patients?
Does vitamin D supplementation in the general population (particularly those who are vitamin D deficient) reduce hospitalisation (or days in hospital) when COVID-19 occurs?
If vitamin D has beneficial effects against COVID-19, it would follow that the severity of the disease should lessen in the Northern hemisphere as exposure to increasing sunlight on the skin in springtime increases endogenous production of vitamin D through the photolysis of 7-dehydrocholesterol.
Our opinion is that if vitamin D does in fact reduce the severity of COVID-19 with regard to pneumonia/ARDS, inflammation, inflammatory cytokines, and thrombosis, then supplements would offer a relatively easy option to decrease the impact of the pandemic.
It is important to recognise that there is a potential for vitamin D toxicity. Consequently, more than the usual daily supplement should only be taken under medical supervision. The efficacy of vitamin D supplements in the prevention of acute respiratory tract infections has best been demonstrated with the chronic intake of low doses, rather than the bolus administration of large doses.14
This is well illustrated by the failure of a single, large enteral dose to improve the outcomes of vitamin D-deficient patients admitted to the intensive care unit (ICU) with pneumonia, sepsis, shock, or respiratory failure, relative to ICU patients given a placebo.15
2. Johnstone J, Parsons R, Botelho F, et al. Immune biomarkers predictive of respiratory viral infection in elderly nursing home residents. PloS One 2014;9:e108481. [PMC free article] [PubMed] [Google Scholar]
3. Fisher SA, Rahimzadeh M, Brierley C, et al. The role of vitamin D in increasing circulating T regulatory cell numbers and modulating T regulatory cell phenotypes in patients with inflammatory disease or in healthy volunteers: A systematic review. PloS One 2019;14:e0222313. [PMC free article] [PubMed] [Google Scholar]
4. Prietl B, Treiber G, Mader JK, et al. High-dose cholecalciferol supplementation significantly increases peripheral CD4+ Tregs in healthy adults without negatively affecting the frequency of other immune cells. Eur J Nutrition 2014;53:751–9. [PubMed] [Google Scholar]
6. Science M, Maguire JL, Russell ML, et al. Low serum 25-hydroxyvitamin D level and risk of upper respiratory tract infection in children and adolescents. Clin Infect Dis 2013;57:392–7. [PMC free article] [PubMed] [Google Scholar]
7. Lips P, Cashman KD, Lamberg-Allardt C, et al. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. Eur J Endocrinol 2019;180:23–54. [PubMed] [Google Scholar]
8. Peterson CA, Heffernan ME. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J Inflamm (London) 2008;5:10. [PMC free article] [PubMed] [Google Scholar]
9. Alhassan Mohammed H, Mirshafiey A, Vahedi H, et al. Immunoregulation of inflammatory and inhibitory cytokines by vitamin D3 in patients with inflammatory bowel diseases. Scand J Immunol 2017;85:386–94. [PubMed] [Google Scholar]
10. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 2020;127:104362. [PMC free article] [PubMed] [Google Scholar]
11. Mohammad S, Mishra A, Ashraf MZ. Emerging role of vitamin D and its associated molecules in pathways related to pathogenesis of thrombosis. Biomolecules 2019;9:649. [PMC free article] [PubMed] [Google Scholar]
13. Melzer S, Zachariae S, Bocsi J, et al. Reference intervals for leukocyte subsets in adults: Results from a population-based study using 10-color flow cytometry. Cytometry B Clin Cytom 2015;88:270–81. [PubMed] [Google Scholar]
14. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017;356:i6583. [PMC free article] [PubMed] [Google Scholar]
More information: PLOS ONE (2020). DOI: 10.1371/journal.pone.0239799